Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
105.35
+0.36 (0.34%)
At close: Nov 13, 2026, 4:00 PM EST
106.15
+0.80 (0.76%)
After-hours: Nov 13, 2026, 7:30 PM EST
Oruka Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Oruka Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $156.17. The average 1-year stock price forecast is 48.24% higher than the current stock price, while the lowest is $117 (+11.06%) and the highest is $200 (+89.84%).
Price Target: $156.17 (+48.24%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Oruka Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Buy Maintains $130 | Buy | Maintains | $130 | +23.40% | Nov 10, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $180 | Buy | Maintains | $180 | +70.86% | Nov 10, 2026 |
Unknown Analyst Guggenheim No rating | Guggenheim | Buy Reiterates $200 | Buy | Reiterates | $200 | +89.84% | Nov 10, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $150 | Buy | Reiterates | $150 | +42.38% | Nov 10, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $120 | Buy | Reiterates | $120 | +13.91% | Nov 10, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.52
from -1.85
EPS Next Year
-2.94
from -2.52
EPS and Forward PE are based on non-GAAP adjusted numbers.